174 related articles for article (PubMed ID: 31962202)
21. Strategies Employed for the Development of PARP Inhibitors.
Canan S; Maegley K; Curtin NJ
Methods Mol Biol; 2017; 1608():271-297. PubMed ID: 28695516
[TBL] [Abstract][Full Text] [Related]
22. Identification of novel PARP-1 inhibitors: Drug design, synthesis and biological evaluation.
Xie Z; Zhou Y; Zhao W; Jiao H; Chen Y; Yang Y; Li Z
Bioorg Med Chem Lett; 2015 Oct; 25(20):4557-61. PubMed ID: 26342868
[TBL] [Abstract][Full Text] [Related]
23. Discovery of 2-(1-(3-(4-Chloroxyphenyl)-3-oxo- propyl)pyrrolidine-3-yl)-1
Min R; Wu W; Wang M; Tang L; Chen D; Zhao H; Zhang C; Jiang Y
Molecules; 2019 May; 24(10):. PubMed ID: 31108884
[TBL] [Abstract][Full Text] [Related]
24. BTH-8, a novel poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor, causes DNA double-strand breaks and exhibits anticancer activities in vitro and in vivo.
Guo C; Zhang F; Wu X; Yu X; Wu X; Shi D; Wang L
Int J Biol Macromol; 2020 May; 150():238-245. PubMed ID: 32057845
[TBL] [Abstract][Full Text] [Related]
25. Discovery of Novel Apigenin-Piperazine Hybrids as Potent and Selective Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors for the Treatment of Cancer.
Long H; Hu X; Wang B; Wang Q; Wang R; Liu S; Xiong F; Jiang Z; Zhang XQ; Ye WC; Wang H
J Med Chem; 2021 Aug; 64(16):12089-12108. PubMed ID: 34404206
[TBL] [Abstract][Full Text] [Related]
26. Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer.
Fu L; Wang S; Wang X; Wang P; Zheng Y; Yao D; Guo M; Zhang L; Ouyang L
Sci Rep; 2016 Dec; 6(1):3. PubMed ID: 28442756
[TBL] [Abstract][Full Text] [Related]
27. Synthesis of Some Benzimidazole-derived Molecules and their Effects on PARP-1 Activity and MDA-MB-231, MDA-MB-436, MDA-MB-468 Breast Cancer Cell Viability.
Gurkan-Alp AS; Alp M; Karabay AZ; Koc A; Buyukbingol E
Anticancer Agents Med Chem; 2020; 20(14):1728-1738. PubMed ID: 32357823
[TBL] [Abstract][Full Text] [Related]
28. Contrasting sirtuin and poly(ADP-ribose)polymerase activities of selected 2,4,6-trisubstituted benzimidazoles.
Yeong KY; Tan SC; Mai CW; Leong CO; Chung FF; Lee YK; Chee CF; Abdul Rahman N
Chem Biol Drug Des; 2018 Jan; 91(1):213-219. PubMed ID: 28719017
[TBL] [Abstract][Full Text] [Related]
29. Synthesis of disaccharide nucleoside analogues as potential poly(ADP-ribose) polymerase-1 inhibitors.
Zheng M; Mex M; Götz KH; Marx A
Org Biomol Chem; 2018 Nov; 16(46):8904-8907. PubMed ID: 30203829
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and Evaluation of a Mitochondria-Targeting Poly(ADP-ribose) Polymerase-1 Inhibitor.
Krainz T; Lamade AM; Du L; Maskrey TS; Calderon MJ; Watkins SC; Epperly MW; Greenberger JS; Bayır H; Wipf P; Clark RSB
ACS Chem Biol; 2018 Oct; 13(10):2868-2879. PubMed ID: 30184433
[TBL] [Abstract][Full Text] [Related]
31. Discovery and SAR study of 2-(1-propylpiperidin-4-yl)-3H-imidazo[4,5-c]pyridine-7-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) for the treatment of cancer.
Zhu Q; Wang X; Hu Y; He X; Gong G; Xu Y
Bioorg Med Chem; 2015 Oct; 23(20):6551-9. PubMed ID: 26422786
[TBL] [Abstract][Full Text] [Related]
32. Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking and Biological Evaluation for Identification of Potential Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors.
Zhou Y; Tang S; Chen T; Niu MM
Molecules; 2019 Nov; 24(23):. PubMed ID: 31766720
[TBL] [Abstract][Full Text] [Related]
33. Design of Selective PARP-1 Inhibitors and Antitumor Studies.
Zhang Y; Li X; Liu F; Bai X; Liu X; Sun H; Gao C; Lin Y; Xing P; Zhu J; Liu R; Wang Z; Dai J; Shi D
J Med Chem; 2024 Jun; 67(11):8877-8901. PubMed ID: 38776379
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis, and biological evaluation of novel chrysin derivatives as poly(ADP-ribose) polymerase 1 (PARP1) inhibitors for the treatment of breast cancer.
Yang Y; Tong J; Xie X; Cao H; Fu Y; Luo Y; Liu S; Chen W; Yang N
Chin J Nat Med; 2024 May; 22(5):455-465. PubMed ID: 38796218
[TBL] [Abstract][Full Text] [Related]
35. Identification of amentoflavone as a potent highly selective PARP-1 inhibitor and its potentiation on carboplatin in human non-small cell lung cancer.
Hu XL; Feng JH; Pham TA; Ma HY; Ma MX; Song R; Shen W; Xiong F; Zhang XQ; Ye WC; Wang H
Phytomedicine; 2018 Nov; 50():88-98. PubMed ID: 30466996
[TBL] [Abstract][Full Text] [Related]
36. Identification of 2-substituted pyrrolo[1,2-b]pyridazine derivatives as new PARP-1 inhibitors.
Xiang HY; Chen JY; Huan XJ; Chen Y; Gao ZB; Ding J; Miao ZH; Yang CH
Bioorg Med Chem Lett; 2021 Jan; 31():127710. PubMed ID: 33246105
[TBL] [Abstract][Full Text] [Related]
37. [Design, synthesis and biological evaluation of novel 3-(2-oxo-2-substituted acetamido)benzamides as PARP-1 inhibitors].
Yin YW; Ji M; Cao R; Chen XG; Xu BL
Yao Xue Xue Bao; 2015 Jun; 50(6):738-45. PubMed ID: 26521446
[TBL] [Abstract][Full Text] [Related]
38. Discovery of Novel Dual Poly(ADP-ribose)polymerase and Phosphoinositide 3-Kinase Inhibitors as a Promising Strategy for Cancer Therapy.
Wang J; Li H; He G; Chu Z; Peng K; Ge Y; Zhu Q; Xu Y
J Med Chem; 2020 Jan; 63(1):122-139. PubMed ID: 31846325
[TBL] [Abstract][Full Text] [Related]
39. Promising anti- cervical carcinoma and inflammatory agent, Resveratrol targets poly (ADP-ribose) polymerase 1 (PARP-1) induced premature ovarian failure with a potent enzymatic modulatory activity.
Alharbi H; Alshehri AS; Ahmad M; Guo WW
J Reprod Immunol; 2021 Apr; 144():103272. PubMed ID: 33465522
[TBL] [Abstract][Full Text] [Related]
40. Synthesis, preliminarily biological evaluation and molecular docking study of new Olaparib analogues as multifunctional PARP-1 and cholinesterase inhibitors.
Gao CZ; Dong W; Cui ZW; Yuan Q; Hu XM; Wu QM; Han X; Xu Y; Min ZL
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):150-162. PubMed ID: 30427217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]